Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The Psoriasis and a chronic dermatosis characterized by abnormal proliferation of cells epithelial, vessel dilation and inflammation locally, which presents erythematous-scaly lesions in various areas of the body, preferably in the scalp, region and religious joints as elbows and knees. It occurs equally in both sexes and can appear at any age, and the mean age for the onset of the disease and around 27.3 years.

The halobetasol propionate and an ultra-potent corticoid. Its chemical structure and similar to the Clobetasol corticoid this, until then classified as the most potent corticoid used worldwide in clinical practice. However, the molecular structure of Halobetasol gives it increased its activity antiinflammatory and anti-proliferative.

The objective of this study is evaluating the efficacy and tolerability of the drug Halobetasol propionate cream formulation as a treatment in patients with plaque psoriasis mild to moderate, compared to the substance of similar power, Clobetasol propionate - Psorex

• Cream.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Azidus Brasil
• Treatments: Clobetasol; Halobetasol

Criteria

Inclusion Criteria:

• Patients of both sexes, adults over 18 years, holders of psoriasis plating of mild to moderate,

• Patients with area of involvement of up to 20% of body surface,

• Patients with good physical and mental health

• Patients who agree with the purposes of the study and sign the Informed Consent

Exclusion Criteria:

• Patients with skin diseases other than psoriasis or which alter the clinical evaluation and development of disease,

• Patients with psoriasis in more than 20% of the body,

• Patients with other types of psoriasis that are not "plating",

• patient with a scalp psoriasis who have difficulty in application of the product,

• Patients who have made topical treatment for psoriasis in the 2 months preceding the study,

• Patients who have made systemic treatment for psoriasis in the 4 months preceding the study,

• Patients who do not agree with the conditions described in the Statement of Informed Consent

• Patients who are pregnant and breastfeeding,

• Patients in use of oral anticoagulants,

• Patients who have psoriatics addition to plaques of skin disorders caused by fungi or bacteria.